

Rabbit anti-Human Wnt-1 Polyclonal Antibody | anti-WNT1 antibody

Anti-Wnt-1 Antibody, Rabbit Polyclonal

CATALOG # AAA257029	HOST Rabbit	REACTIVITY Human	APPLICATIONS Immunohistochemistry
-------------------------------	-----------------------	----------------------------	---


PRODUCT SYNONYMS

Wnt-1; Polyclonal Antibody; Anti-Wnt-1 Antibody; Rabbit Polyclonal; Wnt-1 Antibody; Rabbit PAb; Antigen Affinity Purified; wingless-type MMTV integration site family; member 1; Anti-BMND16 Antibody; Anti-INT1 Antibody; Anti-OI15 Antibody; anti-WNT1 antibody

PRODUCT SPECIFICATIONS


Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Isotype	Rabbit IgG
Specificity	Human Wnt-1
Purity/Purification	Protein A & Antigen Affinity
Form/Format	Liquid; PBS, pH7.0 with 0.03% Proclin300
Applicable Applications for anti-WNT1 antibody	IHC (Immunohistochemistry)
Immunogen	E Coli-derived Human Wnt-1 fragment
Conjugation	Unconjugated
Preparation	Produced in rabbits immunized with E Coli-derived Human Wnt-1 fragment, and purified by antigen affinity chromatography.
Preparation and Storage	This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Avoid repeated freeze-thaw cycles.

IMAGES



IHC (Immunohistochemistry)

Immunochemical staining of human Wnt-1 in human adrenal gland with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.



IHC (Immunohistochemistry)

Immunochemical staining of human Wnt-1 in human liver with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.

ADDITIONAL INFORMATION

Related Product Information for anti-WNT1 antibody	WNT1 mutations in humans are associated with a new form of osteogenesis imperfecta and with early-onset osteoporosis, suggesting a key role of WNT1 in bone mass regulation. Mutations in WNT1 compromise activity of the osteoblasts leading to disturbed bone mass accrual, fragility fractures, and progressive skeletal abnormalities. Wnt1, as a regulator of bone formation and remodeling, provides the basis for the development of Wnt1-targeting drugs for the treatment of osteoporosis. Biallelic loss-of-function mutations in WNT1 cause severe osteogenesis imperfecta (OI) with conspicuous involvement of the spine. OI is a heritable skeletal disorder characterized by bone fragility and low bone mass. Heterozygous missense variants in WNT1 are responsible for early-onset osteoporosis with variable bone phenotypes.
Product Categories/Family for anti-WNT1 antibody	Canonical Wnt Pathway
References	Wang F, et al. (2019) Mesenchymal cell-derived juxtacrine wnt1 signaling regulates osteoblast activity and osteoclast differentiation. J Bone Miner Res 34 (6): 1129-1142.Luther J, et al. (2018) Wnt1 is an lrp5-independent bone-anabolic wnt ligand. Sci Transl Med 10 (466): eaau7137.Alhamdi S, et al. (2018) Heterozygous wnt1 variant causing a variable bone phenotype. Am J Med Genet A 176 (11): 2419-2424.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/polyclonal/wnt-1-antibody-immunohistochemistry-elisa/257029>